Related Experiment Video
Updated: Apr 16, 2026
05:10
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
10.3K
Ethical and public policy challenges for pharmacogenomics
Elliot S Gershon1, Ney Alliey-Rodriguez2, Kay Grennan2
1Department of Psychiatry and Behavioral Neuroscience; Department of Human Genetics; University of Chicago, Illinois, USA.
Dialogues in Clinical Neuroscience
|March 4, 2015
Summary
Pharmacogenomics, using genetic information to guide drug choice, is advancing rapidly. This progress raises significant ethical and policy questions regarding data privacy, drug accessibility, and equitable healthcare, especially for psychiatric disorders.
Area of Science:
- Genomics
- Pharmacology
- Bioethics
Background:
- Pharmacogenomics is crucial for preventing adverse drug reactions and optimizing cancer treatments.
- Genomic-based drug targeting is projected to expand significantly.
- Widespread population genotyping for drug-metabolizing enzyme polymorphisms is proposed to mitigate dangerous drug responses.
Purpose of the Study:
- To examine the ethical and social implications of advancements in pharmacogenomics.
- To highlight policy challenges associated with large-scale genomic data collection and application.
- To underscore the particular relevance of pharmacogenomics policy issues for psychiatric disorders.
Main Methods:
- Review of current advancements and proposed applications of pharmacogenomics.
- Analysis of ethical considerations including consent, data ownership, and accessibility.
- Examination of the role of copy number variation in psychiatric disorders and its policy implications.
Main Results:
- Pharmacogenomic progress necessitates addressing complex ethical and social issues.
- Key policy concerns include data consent, intellectual property, drug testing for rare indications, and treatment accessibility.
- Copy number variations are significant risk factors in psychiatric disorders, intensifying policy challenges.
Conclusions:
- Ethical and policy frameworks must evolve to accommodate the growing use of pharmacogenomics.
- Addressing issues of equity and accessibility is paramount for responsible implementation.
- The intersection of pharmacogenomics and psychiatric disorders presents unique and critical policy challenges.
Keywords:
ethicsgeneticsmental disordermolecular networkpharmacogenomicspopulation geneticspublic policyMore Related Videos
Related Concept Videos
01:29Pharmacogenetics and Pharmacogenomics: Overview
194
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
194
01:29Pharmacogenomics: Identification of New Drug Targets
95
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
95
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
132
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
132
01:27Pharmacogenetics of Drug Metabolism: Overview
157
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
157
01:27Principles of Pharmacogenetics: Types of Genetic Variants
119
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
119
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
257
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
257